Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol.

doi:10.1016/s0022-3565(25)30688-9

Paper

Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol.

Published Nov 1, 1976 · G. Cohen, R. Heikkila, B. Allis

The Journal of pharmacology and experimental therapeutics

Q2 SJR score

111

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

PTTU, diethyldithiocarbamate, methimazole, ethanol, n-butanol, and cysteamine protect sympathetic nerve terminals from 6-hydroxydopamine-induced neurodegeneration, potentially due to their scavenger effects on cytotoxic hydroxy

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol.

Sign up to use Study Snapshot

References

Citations

Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson’s Disease

Protein products from these genes are involved in the earliest stages of Parkinson's disease pathogenesis, suggesting potential therapeutic targets.

Olfactory regulation by dopamine and DRD2 receptor in the nose

Nasal dopamine and DRD2 receptor signaling play important roles in regulating olfactory function, with hunger-induced olfactory enhancement attributed to reduced local DA synthesis.

Cysteamine as a novel disease-modifying compound for Parkinson's disease: Over a decade of research supporting a clinical trial

Cysteamine and its reduced form cysteamine show potential in halting and even reversing neurodegenerative processes in Parkinson's disease models, warranting further clinical trials.

Carvacrol Protects Against 6-Hydroxydopamine-Induced Neurotoxicity in In Vivo and In Vitro Models of Parkinson’s Disease

Carvacrol shows potential neuroprotective effects in Parkinson's disease models, potentially due to its anti-oxidation properties.

1-Phenyl-3-(2-thiazolyl)-2-thiourea inhibits melanogenesis via a dual-action mechanism

PTTU decreases melanin biosynthesis by inhibiting tyrosinase activity and stability, potentially acting as a depigmentation agent for hyperpigmentation disorders.